Recon: Clinical labs trade group sues to block FDA’s LDT rule; FDA expands use of BMS blood cancer drug Breyanzi
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalLaboratory developed tests (LDTs)Medical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicySubmission and registrationUnited States